The MCO-010 vector uses surviving cells in the retina to produce a photosensitive protein that may help patients regain some ...

Cirrus Therapeutics secured an $11 million seed financing led by ClavystBio. Polaris Partners and SEEDS also joined in the ...

A one-time gene therapy called AMT-130 helped slow the progression of Huntington's disease by 75%, paving the way for the ...

Stunning success in halting Huntington's disease with gene therapy offers new hope to those with the disorder—and potential ...

Stanford researchers and their collaborators have revealed a new device that could change the way scientists conduct ...

Cirrus’ lead program is a novel AAV gene therapy designed to restore IRAK-M, a central regulator of the eye’s immune homeostasis, so as to ...

How cell and gene therapy developers can lessen the chances of receiving FDA complete response letters through the use of ...

Universities must do more to provide students with cell and gene therapy manufacturing skills, according to a new study.

Huntington’s disease has been successfully treated for the first time using a gene therapy, which may be available in the US ...

Treatment introduces an expansion of the scope of gene therapies that might lead to similar treatments for neurodegenerative ...

Results from a three-year trial suggest an experimental gene therapy for Huntington's disease can slow the progression of the ...

Preliminary results from a small trial offer the clearest evidence yet that the brain disease’s progression can be slowed.